CBD Oil for Sleep and Spinal Cord Injury: Neurogenic Pain, Autonomic Dysreflexia Sleep Disruption, and the Supraspinal Arousal Disconnection | PureCraft CBD
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Spinal cord injury (SCI) produces the most anatomically determined and level-dependent sleep disruption in this series — a condition in which the location of the injury in the spinal cord (cervical, thoracic, or lumbar), the completeness of the injury (complete vs. incomplete), and the resulting disconnect between supraspinal brain circuits and peripheral body systems all directly shape the specific sleep pathology experienced by the individual. The critical distinction that makes SCI sleep disruption unique in this series: in every other condition — from depression to CKD to TBI — the spinal cord is intact, and the disease process perturbs sleep by acting on the brain, the peripheral organs, or the systemic circulation. In SCI, the spinal cord itself is the site of the primary injury, creating a literal anatomical disconnection between the brain's sleep-regulating systems (the hypothalamus, brainstem, thalamus, basal forebrain) and the peripheral body systems that feed information back to those circuits and that are regulated by descending brain signals. This disconnection has profound consequences for sleep in ways that are not intuitive: the brain's arousal system cannot receive normal afferent (sensory) signals from the body below the injury level, disrupting the sensory homeostasis that normally contributes to sleep regulation; the brain's autonomic outflow cannot effectively regulate peripheral body temperature, blood pressure, and heart rate below the injury level, producing the catastrophic autonomic dysreflexia (AD) that is the most dangerous acute medical event in high-level SCI — and that occurs with high frequency during sleep, producing dramatic nighttime arousal; the spasticity driven by the release of spinal motor circuits from descending inhibition produces the same nocturnal spasticity mechanism as MS (covered in P11-231) but with the additional feature of being constant and independent of disease course, reflecting the permanent structural disconnection rather than the episodic inflammatory demyelination of MS; and the neurogenic pain of SCI — the most mechanistically complex and treatment-resistant pain syndrome in neurology — produces the same nocturnal pain sensitization and sleep fragmentation pattern as other chronic pain conditions but through pathways that are specific to the disconnected spinal cord circuitry. Sleep disturbances affect sixty to eighty percent of people living with SCI, with insomnia and pain-related sleep disruption the most prevalent complaints, and obstructive sleep apnea occurring in forty to sixty percent of cervical (high-level) SCI patients — a rate three to five times higher than the general population due to the respiratory muscle weakness from cervical SCI that reduces pharyngeal muscle tone and ventilatory reserve. The approximately 300,000 Americans living with SCI represent one of the conditions with the highest sleep disruption prevalence and one of the most limited pharmacological treatment options, because the medication interactions and physiological vulnerabilities of SCI restrict the use of standard sleep pharmacotherapy in ways that make non-pharmacological and plant-based approaches particularly valuable for this population.
The SCI sleep disruption profile is uniquely shaped by injury characteristics in a way that no other condition in this series demonstrates — the specific combination of injury level and completeness determines which sleep disruption mechanisms are most prominent for each individual. Cervical SCI (C1–C8) — the highest level, producing tetraplegia/quadriplegia — carries the greatest risk for nocturnal autonomic dysreflexia (because injury above T6 disconnects the splanchnic sympathetic outflow from supraspinal regulation), the highest rate of sleep-disordered breathing (respiratory muscle weakness from cervical injury disrupts upper airway and chest wall mechanics), and the most complete disconnection of central thermoregulatory control over peripheral vasomotor function, producing poikilothermia (inability to regulate body temperature independently of environmental temperature) that directly impairs the normal nocturnal body temperature drop that facilitates sleep onset. Thoracic SCI (T1–T12) — producing paraplegia with intact arm function — has autonomic dysreflexia risk in upper thoracic injuries (T6 and above), with spasticity and neurogenic pain the primary sleep disruptors in mid-to-lower thoracic SCI. Lumbar and sacral SCI — producing incomplete motor and sensory deficits at lower extremity levels — carries the lowest risk of autonomic dysreflexia and sleep-disordered breathing but maintains the neurogenic pain and lower extremity spasticity that drive sleep disruption at this injury level. CBD's potential utility spans the SCI sleep disruption spectrum, with its mechanisms engaging the neurogenic pain (TRPV1 desensitization, CB2/NF-κB, 5-HT1A descending analgesia), spasticity (CB1 spinal motor circuit modulation — the same mechanism validated by nabiximols in MS), and autonomic dysreflexia-related sleep disruption (ANS parasympathetic support for the autonomic instability of high-level SCI) simultaneously — a multi-mechanism profile that is well-suited to the multi-mechanism sleep disruption of SCI.
CBD Oil and SCI Medications: Spasticity Pharmacology, Neuropathic Pain Management, and the SCI Polypharmacy Reality
Baclofen (intrathecal or oral, for SCI spasticity) — no CYP interaction, additive CNS depression, often clinically beneficial combination: Baclofen is the cornerstone pharmacological treatment for SCI-associated spasticity — its GABA-B agonism at spinal cord interneurons reduces the hyperexcitability of deafferented spinal motor circuits that drives SCI spasticity. Intrathecal baclofen (ITB pump) delivers baclofen directly to the CSF, achieving higher spinal cord concentrations with lower systemic exposure. Oral baclofen achieves systemic GABA-B agonism with CNS-depressant effects. As noted in the MS post (P11-231), baclofen has no CYP-mediated pharmacokinetic interaction with CBD. The pharmacodynamic consideration: additive CNS depression between baclofen and CBD. For nocturnal spasticity — where a higher nighttime baclofen dose is commonly used to control spasticity during sleep — the additive CNS depression from CBD may be tolerated and clinically beneficial (facilitating sleep onset and reducing nocturnal spasticity arousals), but can produce excess sedation if CBD dose is high. The clinically meaningful synergy: CBD CB1 modulation of spinal motor circuits and baclofen GABA-B agonism act on different molecular targets within the same spinal cord hyperexcitability mechanism, making the combination potentially additive for spasticity control at doses of each that might be subtherapeutic individually.
Tizanidine (for SCI spasticity) — CYP1A2 substrate, additive hypotension concern amplified in SCI: Tizanidine (Zanaflex) — an alpha-2 adrenergic agonist used for spasticity — is a CYP1A2 substrate with significant hypotension as a primary adverse effect. As noted in the MS post, CBD has modest CYP1A2 inhibitory effects and may modestly elevate tizanidine plasma levels. The SCI-specific concern is amplified: high-level SCI (above T6) produces chronic baseline hypotension from loss of descending vasomotor tone (neurogenic hypotension), and tizanidine further lowers blood pressure through its alpha-2 mechanism. Adding CBD's ANS parasympathetic shift (which also tends to reduce sympathetic vasoconstrictor tone) to the tizanidine-in-neurogenic-hypotension context creates a triple hypotensive risk (neurogenic hypotension + tizanidine + CBD) that can produce symptomatic orthostatic hypotension significant enough to cause pre-syncope in SCI patients already prone to this complication. Blood pressure monitoring during CBD initiation in patients on tizanidine for SCI is essential.
Gabapentin and pregabalin (for SCI neuropathic pain) — no significant CYP interaction, additive CNS depression, pharmacodynamic synergy possible: Gabapentin (Neurontin) and pregabalin (Lyrica) are the most widely used pharmacological treatments for SCI neuropathic pain — their alpha-2-delta calcium channel subunit blockade reduces the ectopic neural discharge of deafferented spinal and peripheral nociceptors. Both are renally eliminated with no significant CYP-mediated interaction with CBD. Additive CNS depression between gabapentin/pregabalin and CBD is the primary concern — both produce sedation, and the combination at high doses of each can produce excess daytime sedation that interferes with SCI rehabilitation activities. The potential benefit: at lower doses of each, the combination may achieve better neuropathic pain control than either agent alone through different mechanisms (gabapentin/pregabalin: alpha-2-delta calcium channel; CBD: TRPV1 desensitization + CB2/NF-κB + 5-HT1A descending analgesia), allowing a lower effective dose of gabapentin/pregabalin that reduces the renal accumulation and sedation burden while maintaining neuropathic pain control. This pharmacodynamic synergy rationale is clinically explored in SCI pain management and is a meaningful consideration for CBD use alongside gabapentin/pregabalin.
Opioids (for refractory SCI neuropathic and musculoskeletal pain) — additive CNS and respiratory depression, most important safety concern in SCI: Opioids (oxycodone, hydrocodone, morphine, fentanyl, methadone, buprenorphine) are used for refractory SCI pain — both neuropathic pain that is incompletely managed by gabapentinoids and musculoskeletal pain from compensatory overuse of intact upper extremity function. The interaction concern is the same as in all chronic pain conditions: additive CNS depression and — critically in high-level cervical SCI — additive respiratory depression. Cervical SCI patients already have reduced respiratory reserve from respiratory muscle weakness (intercostal and abdominal muscle involvement); opioid-induced respiratory depression further reduces ventilatory drive and upper airway muscle tone, increasing the already-elevated OSA risk in this population. CBD at standard supplemental doses adds modest CNS depression to an opioid regimen; the respiratory concern is the dominant safety consideration in cervical SCI patients on opioids. Pain management physician involvement in the decision to add CBD to an existing opioid regimen in SCI is appropriate. The potential opioid-sparing benefit of CBD — through the separate TRPV1/CB2/5-HT1A neuropathic pain mechanisms — may allow opioid dose reduction that reduces the respiratory depression risk more than CBD's own modest effect adds to it, but this requires physician guidance for the opioid taper.
Anticholinergics (oxybutynin, tolterodine for neurogenic bladder) — no significant CYP interaction, additive anticholinergic burden consideration: Neurogenic bladder (detrusor overactivity from loss of suprasacral bladder control after SCI) is managed with anticholinergic agents (oxybutynin, tolterodine, solifenacin) or beta-3 agonists (mirabegron) to reduce detrusor overactivity and the nocturia and urgency that drive nighttime awakenings. Anticholinergics have minimal CYP-mediated interaction with CBD. The pharmacodynamic consideration: anticholinergic agents produce CNS effects (cognitive slowing, sedation, confusion — particularly with oxybutynin's CNS penetration) in addition to their peripheral bladder effects; the additive anticholinergic-plus-CBD CNS depression may worsen daytime cognitive function in SCI patients who are already managing significant cognitive demands. CBD's CB1/TRPV1 modulation of bladder detrusor function (a mechanism highlighted in the MS neurogenic bladder section in P11-231 and the CKD isosthenuria section in P11-232) may provide complementary detrusor tone reduction that could reduce the required anticholinergic dose — a potential benefit for SCI patients seeking to reduce anticholinergic cognitive side effects.
Antidepressants for SCI depression (SSRIs, SNRIs, TCAs) — variable CYP profiles, SCI pain utility of TCAs: Depression affects thirty to forty percent of SCI patients, and antidepressants are commonly prescribed both for depression and for neuropathic pain (TCAs — amitriptyline, nortriptyline — have dual analgesic and antidepressant utility in SCI neuropathic pain; SNRIs — duloxetine, venlafaxine — similarly). SSRI interaction profiles with CBD are as described in the depression, anxiety, and TBI posts: sertraline and escitalopram most favorable. TCAs are CYP2D6 and CYP1A2 substrates — CBD's modest CYP2D6 inhibition may modestly elevate TCA levels; amitriptyline's cardiac conduction effects (QTc prolongation at higher plasma levels) make TCA level monitoring appropriate if CBD is added to an existing TCA regimen. TCAs also have significant anticholinergic effects that compound the anticholinergic burden from neurogenic bladder medications. The overall SCI polypharmacy context — baclofen + gabapentin + oxybutynin + TCA + potentially opioid — creates a cumulative CNS depression burden to which CBD adds one additional modest layer; starting CBD at lower doses and titrating slowly is particularly important in the context of the SCI polypharmacy reality.
How SCI Disrupts Sleep: Anatomical Mechanisms Determined by Injury Level and Completeness
1. Nocturnal Autonomic Dysreflexia: The Most Dangerous SCI Sleep Disruption
Autonomic dysreflexia (AD) is a medical emergency unique to SCI at or above the T6 level — a sudden, massive, uncontrolled sympathetic discharge triggered by a noxious stimulus below the injury level that cannot be regulated by supraspinal parasympathetic counter-regulation because the descending inhibitory pathways have been severed by the injury. Under normal physiology, a noxious stimulus below T6 (a full bladder, fecal impaction, pressure ulcer, tight clothing, urinary tract infection) triggers sympathetic discharge that ascends the spinal cord and is rapidly countered by descending parasympathetic inhibitory signals from the brain — the ANS maintains homeostasis through this supraspinal regulatory feedback loop. In SCI above T6, the ascending sympathetic signal reaches the brain normally (producing the compensatory parasympathetic response above the injury level — bradycardia, facial flushing, sweating, headache), but the descending parasympathetic inhibitory response cannot pass through the injured spinal cord to reach the sympathetic outflow below the injury level. The result: uncontrolled below-injury sympathetic discharge producing severe hypertension (systolic blood pressure spikes of forty to one hundred mmHg above baseline are common; blood pressures exceeding two hundred mmHg can occur) that continues until the triggering stimulus is removed. During sleep, the nocturnal AD triggers include: nocturnal bladder distension (the most common trigger — neurogenic bladder with reduced bladder capacity fills to the point of stimulating detrusor spasm during sleep); nocturnal bowel activity (colonic motility during sleep produces the rectal distension that triggers AD in susceptible SCI patients); pressure point stimulation (prolonged contact pressure against skin at pressure ulcer–prone sites — sacrum, ischium, heels — during immobile sleep); and nocturnal spasticity itself (severe spasticity episodes can produce the nociceptive input that triggers AD). The sleep consequences of nocturnal AD are severe and multi-layered: the hypertensive AD episode is experienced as a pounding headache, profuse sweating, and intense anxiety — all of which produce full arousal from sleep and prolonged awakening; the sympathetic discharge itself fragments sleep architecture by activating the same cortical arousal mechanisms that stress, PTSD, and pain activate; and the need to respond to AD (catheterizing to drain a distended bladder, repositioning, removing constrictive clothing) requires alertness for extended periods, fragmenting sleep into brief intervals. Nocturnal AD occurs in twenty-five to sixty percent of SCI patients with injuries at or above T6 and is among the most devastating sleep disruptors in this population, with severe cases occurring multiple times nightly. CBD's ANS parasympathetic support mechanism is directly relevant to AD: by enhancing parasympathetic tone and reducing sympathetic drive through the CB1/ANS pathway and 5-HT1A mechanism, CBD may reduce the baseline sympathetic hyperreactivity that makes the triggering stimuli more likely to produce full AD episodes rather than the blunted autonomic responses that occur in lower-level SCI. CBD cannot restore the supraspinal descending parasympathetic regulatory pathway — the anatomical disconnection is permanent — but modulating the sympathetic excitability of the deafferented spinal cord circuits through CB1 modulation may reduce the magnitude of autonomous sympathetic discharge at any given triggering stimulus. The CB2/NF-κB mechanism addresses the neuroinflammatory environment of the post-SCI spinal cord that contributes to the hyperexcitability of deafferented sympathetic circuits (neuroinflammation in the perilesional spinal cord upregulates sympathetic interneuron excitability and amplifies AD severity in preclinical SCI models). The prevention of the primary AD triggers — neurogenic bladder management (CBD's CB1/TRPV1 detrusor modulation) and nocturnal spasticity management (CBD's CB1 spinal motor circuit mechanism) — are the most practically impactful CBD contributions to AD prevention during sleep.
2. SCI Neurogenic Pain: The Disconnected Spinal Pain Circuit and Deafferentation Hypersensitivity
SCI neurogenic pain — occurring in sixty to seventy percent of people with SCI and rated as the most disabling SCI complication by many patients, exceeding even paralysis in quality-of-life impact — is the most mechanistically complex pain syndrome in this series and produces the same nocturnal pain sensitization and sleep fragmentation pattern as fibromyalgia, chronic pain, and neuropathic pain conditions but through pathways that are unique to the disconnected spinal cord. SCI neuropathic pain has two spatially distinct components: at-level pain (pain at or immediately adjacent to the injury level, arising from the dorsal horn neurons at the injury margin whose normal afferent input has been eliminated and which develop ectopic firing from deafferentation hypersensitivity) and below-level pain (diffuse burning, dysesthetic pain throughout the body below the injury level — the most common pattern — arising from the ascending spinal thalamic tract neurons at and above the injury that lose their normal inhibitory modulation from below-injury afferents and develop central sensitization). The central sensitization of SCI neuropathic pain is qualitatively different from the central sensitization of fibromyalgia or PTSD hyperalgesia: in fibromyalgia, the central sensitization involves a globally sensitized but anatomically intact pain modulation system. In SCI, the central sensitization occurs in deafferented spinal cord neurons (the dorsal horn interneurons and spinothalamic tract neurons that have lost their normal afferent input and whose spontaneous discharge is no longer regulated by normal peripheral sensory traffic) — producing a pain signal that exists without peripheral tissue injury and that cannot be silenced by the normal peripheral-to-central inhibitory mechanisms that modulate pain in intact spinal cord function. The nocturnal amplification of SCI neuropathic pain: as in all chronic neuropathic pain, the relative quiet of nighttime (reduced competing sensory input from daytime activity, thermal fluctuations in the bedroom environment triggering temperature-sensitive nociceptor discharge, and the circadian reduction in endogenous opioid and serotoninergic descending pain inhibition in the early morning hours) produces the nocturnal amplification of below-level burning dysesthesias that is the hallmark sleep disruptor of SCI neuropathic pain. CBD's TRPV1 desensitization is particularly relevant for SCI neuropathic pain: TRPV1 receptors on the central terminals of primary afferents at the dorsal horn, and on the deafferented dorsal horn interneurons themselves, are upregulated in SCI and contribute to the ectopic firing of deafferented pain-signaling neurons. TRPV1 desensitization at these central terminals reduces the ectopic discharge that sustains the SCI pain signal independent of peripheral input. The CB2/NF-κB mechanism reduces the neuroinflammatory environment of the injured spinal cord — microglial activation and NLRP3 inflammasome-driven IL-1β and TNF-α production are elevated at the perilesional spinal cord and amplify dorsal horn hyperexcitability. The 5-HT1A mechanism supports the descending serotoninergic inhibitory pathway from the raphe-spinal tract that is disrupted (though not severed) in SCI — ascending raphe-spinal serotonergic axons that run in the dorsal columns and lateral funiculi can be partially preserved in incomplete SCI, and 5-HT1A partial agonism at the remaining serotoninergic synapses may partially restore descending pain inhibition that was reduced by the SCI.
3. Nocturnal SCI Spasticity: The Permanent Structural Release of Spinal Motor Circuits
SCI spasticity — occurring in sixty to seventy percent of people with incomplete or complete SCI above the lumbosacral level — is driven by the same fundamental mechanism as MS nocturnal spasticity (P11-231) but with a critical structural difference: in MS, spasticity arises from episodic demyelination of the descending corticospinal motor tracts in the white matter; in SCI, the structural disconnection of the corticospinal tract at the injury level permanently releases the spinal motor circuits below the injury from descending inhibitory control. The deafferented spinal motor circuits — the alpha and gamma motor neurons and their interneuronal networks below the injury level — develop intrinsic hyperexcitability from the loss of descending inhibitory monoaminergic (serotonergic and noradrenergic) input that normally maintains spinal motor circuit excitability in a physiological range. This results in the characteristic SCI spasticity pattern: spontaneous spasms (uninhibited motor neuron discharge producing sudden involuntary limb movements), increased muscle tone (velocity-dependent resistance to passive movement from hyperactive muscle spindle stretch reflexes), clonus (rhythmic motor neuron oscillation), and the nocturnal flexor spasms that are particularly disruptive to sleep. The nocturnal SCI spasticity pattern reflects the same circadian modulation as MS spasticity: the nocturnal reduction in descending serotoninergic and noradrenergic tone from the brainstem (which is intact above the SCI, but cannot deliver its inhibitory signals below the injury level through the severed cord) produces maximal deafferentation of the spinal motor circuits during sleep, allowing spontaneous spasm generation to reach its circadian peak in the early morning hours. Thermal triggers — the nightly temperature drop of the bedroom environment — activate thermosensitive afferents in intact dermatomes above the injury level that project to spinal interneurons above the injury, triggering reflex arcs that propagate below the injury through propriospinal circuits, generating flexor spasms in the paralyzed limbs. CBD's CB1 spinal motor circuit modulation — the same mechanism validated by nabiximols (THC:CBD 1:1) for MS spasticity, which produces CB1 agonism at interneurons in the injured and deafferented spinal cord — is directly applicable to SCI spasticity. CB1 receptors are expressed on the deafferented spinal motor interneurons, and CB1 agonism reduces the hyperexcitable spontaneous discharge of these circuits through the same inhibitory mechanism that modulates corticospinal activity in intact circuits. Importantly, cannabinoids consistently show the strongest spasticity evidence in SCI patients: the clinical evidence base for cannabinoid benefit in SCI spasticity (from surveys of SCI patients who use cannabis medically, and from the nabiximols SCI clinical trials data) is among the strongest in the cannabinoid-spasticity literature — comparable to or stronger than the MS spasticity evidence that resulted in nabiximols approval.
4. Supraspinal Arousal Disconnection and Thermoregulatory Sleep Disruption in Cervical SCI
High-level cervical SCI (C1–C8) produces two sleep disruption mechanisms that are specific to the completeness and level of injury and that have no equivalent in any other condition in this series: supraspinal arousal disconnection from peripheral sensory afferents and thermoregulatory poikilothermia. Normal sleep depends on a complex integration of sensory afferent information from the entire body — proprioceptive signals from muscle spindles and joint receptors, cutaneous thermoreceptors and mechanoreceptors, visceral afferents from the gut, bladder, and cardiovascular system — that all converge on the hypothalamic and thalamic arousal-regulating circuits through intact spinal cord relay pathways. This peripheral sensory traffic contributes to the maintenance of the thalamic arousal state and the regulation of NREM sleep transitions. In complete cervical SCI, the loss of all sensory afferent input from below the injury level produces a form of sensory deprivation of the arousal circuits — the hypothalamus and thalamus receive dramatically reduced afferent input from the largest portion of the body's surface and internal organs. The paradoxical effect: the brain's arousal circuits, deprived of their normal peripheral sensory regulatory input, may show abnormal sleep architecture — disrupted N3 generation and altered NREM-REM cycling — in part because the normal sensory regulation of sleep depth and transitions is absent. Thermoregulatory poikilothermia: normally, the hypothalamic thermoregulatory center coordinates peripheral vasomotion and sweating to produce the nocturnal core body temperature drop (approximately 0.5–1°C) that is a critical physiological facilitator of sleep onset — the body cools by redistributing heat from the core to the periphery through cutaneous vasodilation. In high-level cervical SCI, the descending thermoregulatory commands from the hypothalamus cannot reach the peripheral vasculature below the injury level, because the sympathetic preganglionic neurons that drive cutaneous vasodilation are disconnected from supraspinal control at the injury level. The result: the SCI patient cannot actively regulate peripheral skin temperature below the injury level, producing passive environmental-temperature-dependent skin temperature change that may not produce the controlled nocturnal core temperature reduction needed for normal sleep onset. In warm environments, the inability to dissipate heat through below-injury cutaneous vasodilation leads to core temperature retention that impairs sleep onset; in cold environments, the inability to produce vasoconstrictive heat conservation below the injury level leads to excessive heat loss and thermal discomfort. CBD's ANS parasympathetic support contributes to the above-injury thermoregulatory mechanisms that remain intact (facial and upper thoracic vasodilation and sweating above the injury level, which can partially compensate for below-injury thermoregulatory loss in incomplete SCI). The melatonin component of the gummies — which serves as a circadian anchor for the sleep onset signal — partially compensates for the disrupted thermal sleep onset signal by providing a direct circadian signal for sleep initiation that does not depend on the thermoregulatory pathway.
SCI Level, Completeness, and CBD Protocol Relevance
| SCI Profile | Dominant Sleep Disruption | CBD Mechanism Priority | Protocol Note |
|---|---|---|---|
| Cervical SCI (C1–C8) — Tetraplegia/Quadriplegia | Nocturnal AD; OSA; thermoregulatory poikilothermia; spasticity; neuropathic pain | ANS parasympathetic for AD mitigation; CB1 for spasticity + bladder (AD prevention); TRPV1 pain; melatonin for thermal sleep onset | OSA evaluation required; opioid respiratory caution; tizanidine hypotension monitoring; ITB baclofen compatibility |
| Upper Thoracic SCI (T1–T6) — AD risk zone | Nocturnal AD; spasticity; neuropathic pain; neurogenic bladder nocturia | ANS for AD risk; CB1 spasticity; TRPV1/CB2 pain; CB1/TRPV1 detrusor for AD trigger prevention | AD prevention through bladder management is key; baclofen + CBD synergy for nocturnal spasticity |
| Lower Thoracic SCI (T7–T12) — no AD risk | Spasticity; neuropathic pain; neurogenic bladder nocturia | CB1 for spasticity; TRPV1/CB2/5-HT1A pain; CB1/TRPV1 bladder; 5-HT1A HPA for co-occurring depression | No AD concern; gabapentin interaction review (most common combination here); baclofen timing |
| Lumbar/Sacral SCI — Cauda Equina / Lower Extremity | Neuropathic pain; lower extremity weakness/spasm; neurogenic bladder; depression | TRPV1/CB2 neuropathic pain (dominant); 5-HT1A depression; HPA/FAAH cortisol; CB1/TRPV1 bladder | Most favorable overall safety profile; standard dose range appropriate; gabapentin/SSRI combination review |
Population Profiles
High-Level SCI with Nocturnal AD and Spasticity: The AD-Prevention-First Protocol
For people with cervical or upper thoracic SCI (above T6) where nocturnal autonomic dysreflexia and spasticity are the dominant sleep disruptors, the CBD protocol is structured around AD prevention through the two mechanisms most responsible for nocturnal AD triggering: neurogenic bladder distension and nocturnal spasticity. The Nano CBD Broad Spectrum Oil taken sixty to ninety minutes before sleep provides the CB1/TRPV1 detrusor modulation that reduces bladder overactivity (the primary AD trigger during sleep) and the CB1 spinal motor circuit modulation that begins reducing spasticity during the pre-sleep window (the second most common nocturnal AD trigger). The ANS parasympathetic support of the oil reduces the baseline sympathetic tone that amplifies AD severity — a direct AD-mitigation mechanism independent of trigger prevention. The Nano CBD Water-Soluble Broad Spectrum Softgels at sleep onset provide sustained overnight CB1 spasticity control and TRPV1 neuropathic pain desensitization that together address both the spasticity-triggered AD episodes and the pain-driven arousals that fragment sleep in the second half of the night. The Nano CBD Muscle & Joint Cream applied to spastic muscle groups (typically the lower extremities) provides local TRPV1 and CB1 modulation at the peripheral sensory afferents and muscle tissue without systemic opioid-additive CNS depression — important for cervical SCI patients where respiratory function is already compromised. The CBD+CBN+D9+Melatonin Gummies provide the melatonin circadian anchor that partially compensates for the thermoregulatory sleep onset disruption of cervical SCI (where the body cannot produce the normal nocturnal temperature drop through below-injury vasodilation) and the CBN N3 architecture promotion for the deep sleep restoration that is reduced by multiple nighttime arousals from AD and spasticity. Physician (physiatrist or SCI rehabilitation specialist) disclosure is essential given the opioid respiratory, tizanidine hypotensive, and baclofen additive sedation interaction landscape.
Lower-Level SCI with Neuropathic Pain and Spasticity: Pain-First Sleep Protocol
For people with thoracic, lumbar, or sacral SCI where neuropathic pain is the dominant sleep disruptor and AD risk is absent (below T6) or minimal, the CBD protocol centers on the multi-mechanism neuropathic pain approach. The Nano CBD Broad Spectrum Oil forty-five minutes before sleep addresses the nocturnal pain sensitization and hyperarousal that dominate sleep onset disruption; the 5-HT1A mechanism supports the serotoninergic descending inhibitory pathway that is disrupted by SCI and that is responsible for the sleep-time amplification of below-level burning dysesthesias. The Nano CBD Muscle & Joint Cream applied to the lower extremities — the most common location of SCI below-level burning neuropathic pain — provides local TRPV1 desensitization and CB2 modulation at the skin surface that can reduce the peripheral thermoreceptor and mechanoreceptor input that, even in regions of reduced sensation, can contribute to the central sensitization maintaining the below-level pain signal. For patients on gabapentin or pregabalin for neuropathic pain: the CBD combination may allow dose reduction of gabapentinoids through the complementary TRPV1/CB2/5-HT1A pain mechanism — a clinically relevant benefit for reducing gabapentinoid-associated cognitive side effects that interfere with SCI rehabilitation and daytime function. The CBD+CBN+D9+Melatonin Gummies for N3 architecture restoration and the Nano CBD Broad Spectrum Gummies for daytime anti-inflammatory maintenance of the ongoing neuroinflammatory neuropathic pain process complete the protocol for this population.
CBD Oil Protocol for SCI Sleep Disruption
The SCI Sleep Protocol: Level-Appropriate, AD-Prevention Priority, Multi-Delivery
Identify the dominant sleep disruptor by injury level: The protocol priority is shaped by injury level. Above T6 — AD prevention comes first: bladder management (CBD CB1/TRPV1 detrusor modulation) and spasticity control (CBD CB1 spinal motor) are the most impactful mechanisms for reducing the nocturnal AD triggers that produce the most disruptive awakenings. Below T6 — neuropathic pain management is the primary focus: TRPV1/CB2/5-HT1A pain mechanisms through oil and cream delivery.
Multi-delivery route approach is standard SCI protocol: Because SCI patients commonly have paralyzed lower extremities where pain and spasticity are concentrated but systemic drug delivery is complicated by the polypharmacy interaction landscape, the combination of systemic CBD (oil, softgels, gummies) for central mechanisms and topical CBD (cream for limbs) for local peripheral mechanisms is the most clinically rational approach — and the combination that reduces the systemic CNS depression burden while maintaining local efficacy.
Physiatrist disclosure and SCI rehabilitation team integration: SCI care is typically managed by a physiatrist (physical medicine and rehabilitation physician) and an interdisciplinary SCI rehabilitation team. Disclosure of CBD use to the physiatrist is essential for the medication interaction review (baclofen, tizanidine, gabapentin, opioids, anticholinergics, antidepressants) and for ensuring that CBD's effects on spasticity, pain, and bladder function are appropriately interpreted in the context of ongoing rehabilitation monitoring.
OSA evaluation for all cervical SCI: The forty to sixty percent OSA rate in cervical SCI makes sleep apnea evaluation (polysomnography) standard for all cervical SCI patients with sleep complaints. CBD addresses sleep architecture and pain/spasticity but does not treat upper airway obstruction. Untreated OSA is both a significant sleep disruptor and a cardiovascular risk factor that CBD cannot substitute for CPAP or positional therapy in addressing.
Spasticity-monitoring protocol adjustment: SCI spasticity is not always purely negative — many SCI patients with complete lower extremity paralysis depend on spasticity-maintained muscle tone for transfer assistance, positioning, and in some cases for functional standing. An increase in CBD dose that meaningfully reduces spasticity should be reviewed with the physiatrist to ensure it does not reduce the functional spasticity that the patient relies on for rehabilitation and daily activities.
PureCraft Products for SCI Sleep Disruption
Pre-Sleep ANS Support and AD Mitigation: Oil for Bladder, Spasticity, and Sympathetic Tone
The Nano CBD Broad Spectrum Oil taken sixty to ninety minutes before sleep — with a longer pre-sleep interval than most conditions in the series — provides the CB1/TRPV1 detrusor modulation that reduces neurogenic bladder overactivity in the pre-sleep window (critical for reducing the nighttime bladder distension that is the most common AD trigger), the CB1 spinal motor circuit modulation that reduces baseline spasticity during sleep preparation, and the ANS parasympathetic shift that reduces the sympathetic excitability driving AD severity. The extended pre-sleep interval (sixty to ninety minutes rather than the standard forty-five) ensures that peak plasma CBD coincides with the pre-sleep bladder management window before catheterization (for those on intermittent catheterization schedules). For SCI patients with above-T6 injuries where AD is the dominant concern: the oil is the most time-critical pre-sleep CBD delivery, because its bladder and sympathetic tone effects are needed during the window of falling asleep when the transition to sleep (reduced consciousness, inability to respond immediately to bladder distension) is when AD risk is highest. The TRPV1 desensitization and CB2/NF-κB mechanisms begin addressing the neuropathic pain central sensitization during the pre-sleep period, reducing the pain-driven hyperarousal that prevents sleep initiation alongside the AD and spasticity management.
Local Limb Spasticity and Pain: Cream as Standard SCI Protocol
The Nano CBD Muscle & Joint Cream applied to spastic muscle groups and areas of neuropathic pain (most commonly the lower extremities — thighs, hamstrings, calves, feet — for thoracic and lumbar SCI) provides local TRPV1 desensitization and CB1-mediated peripheral motor tone modulation at the site of the greatest symptom burden without adding to the systemic CNS depression from the existing SCI medication regimen. For cervical SCI patients who cannot self-apply cream to their lower extremities (requiring caregiver assistance for the cream application), scheduling cream application as part of the pre-sleep caregiver routine — applied during the same session as catheterization, repositioning, and nighttime positioning — integrates seamlessly into the existing SCI nighttime care workflow. The cream's local therapeutic effect on the neuropathic burning dysesthesias of below-level SCI pain — particularly the feet, calves, and thighs — provides direct peripheral TRPV1 desensitization at the skin surface that reduces the thermosensitive input maintaining central sensitization during the nocturnal temperature fluctuations of the sleep environment. For SCI patients with pressure-sensitive skin (reduced sensation increasing pressure injury risk): cream application follows the same caution as any topical product applied to reduced-sensation skin — application only to intact skin, avoiding areas of redness, and caregivers visually confirming intact skin before and after application.
Overnight Spasticity and Pain Control: Softgels for Sustained Coverage
The Nano CBD Water-Soluble Broad Spectrum Softgels at sleep onset provide the sustained overnight CB1 spasticity control and TRPV1/CB2 neuropathic pain desensitization that maintain coverage through the entire overnight period — particularly the second half of the night when circadian serotoninergic and noradrenergic inhibitory tone is at its nadir and neuropathic pain and spasticity intensity are at their circadian peak. The sustained-release pharmacokinetics ensure that CB1 spinal motor modulation is maintained through the early morning hours (three to six AM) when nocturnal spasticity episodes and early-morning below-level pain intensification are most common in SCI. For SCI patients on intrathecal baclofen (ITB pump): the sustained overnight CBD softgel coverage complements the ITB's continuous intrathecal GABA-B agonism through the separate CB1 molecular target, and the combination at standard doses of each is generally well-tolerated in SCI clinical experience — but the physiatrist managing the ITB pump should be aware of the combination for appropriate monitoring of overall spasticity level and ITB dose adjustment if combined spasticity reduction is excessive.
Sleep Architecture and Circadian Anchoring: Gummies for N3 and Thermoregulatory Compensation
The CBD+CBN+D9+Melatonin Gummies taken sixty to ninety minutes before sleep provide the N3 architecture promotion (CBN) that restores the deep slow-wave sleep that is fragmented by recurrent AD episodes, spasticity arousals, and pain awakenings across the first and second halves of the night. The melatonin component serves a particularly important role in high-level cervical SCI: because the thermoregulatory poikilothermia of cervical SCI impairs the normal nocturnal core body temperature reduction that is a critical physiological cue for sleep onset, the melatonin's direct circadian signaling for sleep onset partially compensates for this lost thermal sleep onset signal through an independent (pineal-circadian) pathway. The circadian anchoring function of melatonin — combined with the N3-promoting CBN — supports the restoration of sleep architecture quality that multiple nightly arousals from SCI-specific disruptors (AD, spasticity, pain, bladder urgency) have fragmented. The Nano CBD Broad Spectrum Gummies for daytime maintenance support the continuous CB2/NF-κB anti-inflammatory reduction of the neuroinflammatory environment at the perilesional spinal cord — the ongoing neuroinflammatory process that sustains both neuropathic pain central sensitization and spinal motor circuit hyperexcitability in chronic SCI, and that requires consistent daily anti-inflammatory coverage rather than nighttime-only CBD for maximum effect on the chronic neuroinflammatory burden of SCI.
Frequently Asked Questions About CBD Oil for Spinal Cord Injury Sleep Disruption
Can CBD oil help with the spasms that wake me up at night after spinal cord injury?
Nocturnal spasticity in SCI — the sudden involuntary limb spasms that cause full arousal from sleep, often with pain from the spasm's intensity or from the limb's movement against the bed surface — is one of the most mechanistically well-suited SCI symptoms for CBD intervention. The mechanism of SCI nocturnal spasticity is the release of the spinal motor circuits below the injury level from descending inhibitory control: without the tonic inhibitory influence of corticospinal and reticulospinal descending tracts, the alpha motor neurons of the spinal cord below the injury develop intrinsic hyperexcitability and generate spontaneous discharge — spasms — that are amplified nocturnally by the circadian reduction in descending monoaminergic tone from the brainstem. CBD's CB1 mechanism — which modulates the excitability of these same deafferented spinal interneurons and motor neurons through CB1 receptor-mediated presynaptic inhibition of excitatory neurotransmitter release — directly targets the spasm-generating mechanism. The clinical evidence base for cannabinoid benefit in SCI spasticity is notably strong: multiple surveys of SCI patients who use medical cannabis report spasticity relief among the highest-rated benefits, with subjective reduction in spasm frequency and intensity being the most consistently reported effect. The nabiximols (THC:CBD 1:1) clinical evidence for spasticity — which led to regulatory approval in multiple countries for MS spasticity — includes SCI populations in some trials, with SCI patients showing equal or greater response than MS patients in spasticity score reduction. For nocturnal SCI spasticity specifically: the combination of the sustained-release softgel at sleep onset (for overnight CB1 coverage through the early morning spasm peak) and the cream applied to the spastic limbs (for local CB1/TRPV1 peripheral modulation) provides both systemic and local spasticity control simultaneously. The most important consideration: as noted in the protocol section, functional spasticity (the spasticity that SCI patients depend on for transfers, standing, or other ADL assistance) should be preserved — the goal is reducing disruptive nocturnal spasms while maintaining functional daytime spasticity level, which requires communication with the physiatrist about the spasticity monitoring goals.
What is autonomic dysreflexia and can CBD oil help with the sleep disruption it causes?
Autonomic dysreflexia (AD) is a medical emergency unique to SCI at or above the T6 spinal cord level — a sudden, uncontrolled surge of sympathetic nervous system activity triggered by a noxious stimulus below the injury level that cannot be regulated by the brain's normal parasympathetic counter-response because the spinal cord injury has severed the descending inhibitory pathway. During normal physiology, if something uncomfortable happens below T6 (a full bladder, constipation, a skin pressure point), the sympathetic nervous system activates and the brain immediately sends a parasympathetic braking signal down the spinal cord to dampen it. In SCI above T6, that braking signal cannot reach below the injury. The sympathetic system fires uncontrolled — blood pressure spikes dramatically (sometimes above 200 mmHg systolic), the person experiences a pounding headache, profuse sweating, flushing above the injury, and intense anxiety. During sleep, when the person cannot feel or respond immediately to the triggering stimulus, these episodes produce full arousal from deep sleep and can occur multiple times nightly in people with poorly controlled neurogenic bladder or recurrent pressure point triggers. CBD's role in AD management addresses both the trigger prevention and the sympathetic magnitude components of the AD mechanism. For trigger prevention — neurogenic bladder distension (the most common nocturnal AD trigger): CBD's CB1/TRPV1 modulation of the detrusor muscle reduces bladder overactivity, potentially increasing functional bladder capacity and reducing the urgency-to-spasm threshold that triggers AD before catheterization can occur. For spasticity-triggered AD: CBD's CB1 spinal motor modulation reduces nocturnal spasm intensity, which reduces the nociceptive input from spasms that can trigger AD in susceptible high-level SCI patients. For the sympathetic magnitude itself: CBD's ANS parasympathetic shift — the enhancement of parasympathetic tone through CB1/ANS and 5-HT1A mechanisms — may reduce the baseline sympathetic excitability of the deafferented spinal cord circuits that determines how severely any given trigger produces a full AD episode versus a blunted autonomic response. CBD is not a treatment for acute AD — if an AD episode occurs, the immediate response is to sit the patient up (orthostatic position reduces blood pressure), identify and remove the triggering stimulus (catheterize the bladder, check for fecal impaction, relieve pressure points), and seek emergency care if blood pressure does not resolve. The role of CBD is in the chronic management of AD trigger frequency and sympathetic hyperexcitability — a preventive rather than acute treatment rationale.
Can CBD oil help with the burning pain below my injury level that keeps me from sleeping?
Below-level SCI neuropathic pain — the diffuse burning, dysesthetic, electric-shock pain felt throughout the body below the injury level despite absent or reduced sensation — is one of the most treatment-resistant and quality-of-life-impairing symptoms of SCI, rated by many patients as more disabling than their paralysis. The nocturnal amplification of this below-level burning pain is driven by the circadian reduction in descending serotoninergic and noradrenergic pain inhibition (the brainstem raphe and locus coeruleus pain-inhibitory systems reduce their inhibitory output in the early morning hours — three to five AM — producing the circadian pain peak that wakes SCI patients from sleep), combined with the thermal and mechanical sensitivity of the skin surface during sleep (temperature changes as the bedroom environment cools overnight activate thermoreceptors that, even in regions of partial sensation, contribute to the central sensitization maintaining the below-level pain signal). CBD's mechanisms for below-level SCI neuropathic pain address this through multiple complementary pathways. The TRPV1 desensitization — the most directly relevant mechanism — acts on TRPV1 receptors on the deafferented dorsal horn interneurons at the injury margin and on the central terminals of any remaining primary afferents (preserved in incomplete SCI) that contribute to the ectopic firing sustaining the below-level pain signal. TRPV1 desensitization reduces both the heat-evoked activation of thermosensitive TRPV1 (responsible for the temperature-sensitive worsening of below-level burning) and the tonic ectopic discharge of deafferented dorsal horn TRPV1-expressing neurons. The CB2/NF-κB mechanism reduces the microglial neuroinflammation at the perilesional spinal cord (the dorsal horn neuron hyperexcitability in SCI is maintained by ongoing microglial activation producing TNF-α and IL-1β that lower dorsal horn firing thresholds) — addressing the inflammatory amplification of central sensitization at its source. The 5-HT1A mechanism partially restores the descending serotoninergic inhibitory pathway from the raphe nuclei — the same pathway whose circadian withdrawal causes the early-morning pain peak that wakes SCI patients. For maximum nocturnal pain coverage: the combination of oil pre-sleep (5-HT1A and TRPV1 onset) + softgel at sleep onset (sustained overnight CB2 and TRPV1 coverage) + cream to the burning extremities (local TRPV1 desensitization at the skin surface temperature sensors) provides the most comprehensive multi-mechanism below-level pain coverage available from a CBD protocol.
Is CBD oil safe to use with baclofen and gabapentin for spinal cord injury?
The baclofen + gabapentin + CBD combination is the most common SCI polypharmacy context for CBD sleep support, and the interaction profile is manageable with appropriate awareness. Baclofen: no CYP-mediated pharmacokinetic interaction with CBD — the combination is pharmacologically compatible from a metabolism standpoint. The relevant concern is additive CNS depression: baclofen at doses used for SCI spasticity (often sixty to eighty milligrams per day total, sometimes higher) produces significant CNS sedation; adding CBD's modest CNS depression requires dose awareness for excess sedation, particularly in the first week of CBD initiation. The clinically relevant benefit of the baclofen + CBD combination: both reduce SCI spasticity through different molecular targets (baclofen through GABA-B agonism at spinal interneurons; CBD through CB1 modulation of spinal motor circuits), producing potentially additive spasticity reduction at lower doses of each than would be required of either agent alone. This complementary mechanism combination is recognized in the SCI spasticity management literature. Gabapentin: also no CYP-mediated interaction with CBD — gabapentin is renally eliminated without hepatic CYP metabolism. The additive CNS depression concern is the same as with baclofen: the three-way CNS-depressant combination of baclofen + gabapentin + CBD requires lower starting CBD doses and slower titration to avoid excess daytime sedation that interferes with SCI rehabilitation. The benefit: CBD's separate TRPV1/CB2/5-HT1A neuropathic pain mechanisms complement gabapentin's alpha-2-delta calcium channel mechanism, potentially improving overall neuropathic pain control with less gabapentin-required sedation. The recommended approach: when initiating CBD alongside an existing baclofen + gabapentin regimen, start at twenty-five to fifty percent of the standard CBD starting dose, assess at two weeks, and titrate slowly — and inform the physiatrist of the combination so that spasticity and pain monitoring can be interpreted in the context of the multi-agent regimen. If the baclofen + gabapentin + CBD combination produces better spasticity and pain control, the physiatrist may be able to reduce one or both existing medications to reduce the overall CNS depression burden while maintaining the therapeutic benefit through the complementary CBD mechanism.
Why do I sleep so poorly even though I can't feel anything below my injury — I thought pain was the reason?
This question reflects one of the most counterintuitive aspects of SCI sleep disruption and gets at the supraspinal arousal disconnection mechanism that is unique to SCI in this series. The expectation — that losing sensation below the injury should reduce sleep disruption because there is less sensory input — is exactly wrong in practice, and for a mechanistically interesting reason. Normal sleep regulation is not simply the absence of painful stimuli — it is the active integration of a rich stream of afferent sensory information from the entire body (proprioception, cutaneous mechanoreception, thermoreception, visceral afferents from gut, bladder, and cardiovascular system) into the hypothalamic and thalamic circuits that regulate sleep depth, sleep stage transitions, and arousal thresholds. This constant afferent traffic is not a source of arousal — it is a source of regulatory information that helps the brain maintain stable sleep. When this afferent traffic is eliminated by SCI (in complete SCI, the brain receives no sensory input from below the injury level), the hypothalamic and thalamic sleep-regulating circuits lose a major input stream that contributes to their normal function. The result, paradoxically, is more unstable sleep — not less arousal, because the normal arousal-suppressing, sleep-stabilizing sensory regulatory input has been eliminated. Beyond this mechanism, high-level SCI patients experience sleep disruption from sources that are not consciously perceptible: nocturnal AD episodes (blood pressure spikes that produce cortical arousal and awakening even before the patient is consciously aware of the AD headache), nocturnal spasticity spasms (motor events that produce EEG arousal and fragmented sleep even when the patient does not consciously awaken from them), and the thermoregulatory poikilothermia that prevents the normal nocturnal core body temperature drop from occurring, making physiological sleep onset harder regardless of sensation level. So even for complete SCI patients who cannot feel below their injury, the body is generating multiple sleep-disrupting events — AD, spasticity, thermal dysregulation, bladder distension — that produce EEG arousals, sleep stage fragmentation, and architectural deterioration whether or not the patient is consciously aware of the triggering event. CBD's mechanisms for this supraspinal disconnection — ANS parasympathetic support for sympathetic hyperreactivity, CB1 spasticity reduction, CB1/TRPV1 bladder modulation, and melatonin for thermal sleep onset compensation — address the actual biological sources of the sleep disruption rather than the perceived symptom burden, which is why the effect of CBD on SCI sleep quality may be experienced as improved sleep continuity and refreshedness even for patients who cannot consciously feel the symptoms being addressed.
How long does it take for CBD oil to help with sleep after spinal cord injury, and what should I expect?
The timeline and realistic expectations for CBD sleep benefit in SCI differ meaningfully from acute conditions and from chronic systemic conditions, because SCI sleep disruption arises from permanent structural changes (the injury-level disconnection) rather than from reversible physiological perturbations. This means that CBD is not treating the underlying structural SCI pathology — it is modulating the functional consequences (spasticity, neuropathic pain, bladder overactivity, autonomic excitability) that are driven by that permanent structural change. The practical expectation timeline: the acute responses to CBD — the ANS parasympathetic shift, the initial CB1 spinal motor modulation, and the pre-sleep bladder detrusor modulation — can show effects within the first one to two weeks, and some SCI patients report noticeable reduction in nocturnal spasticity intensity and pre-sleep bladder urgency within this window. The neuropathic pain response — which depends on the progressive TRPV1 desensitization and CB2 neuroinflammatory modulation — is typically slower, with the full benefit appearing over four to eight weeks of consistent use. The sleep architecture improvement from the CBN N3 promotion in the gummies — which addresses the architectural fragmentation from multiple nightly AD, spasticity, and pain arousals — requires the consistent reduction of those arousals over the first four to eight weeks before the architectural benefit becomes measurable in terms of subjective sleep quality and daytime function. Realistic expectations: CBD will not eliminate AD, spasticity, or SCI neuropathic pain — it is a complementary mechanism among the multi-drug, multi-therapy SCI management approach. The realistic benefit is a meaningful reduction in nocturnal spasticity episodes, a reduction in the bladder urgency that triggers nighttime AD, an improvement in neuropathic pain intensity that allows sleep initiation and maintenance more easily, and a sleep architecture improvement from fewer awakenings that is reflected in better daytime energy, cognitive function, and rehabilitation capacity. For SCI patients with particularly refractory nocturnal spasticity or pain that significantly limits sleep quality: discussion with the physiatrist about the specific CBD + baclofen or CBD + gabapentin combination, with the possibility of dose optimization across the combined regimen, is likely to produce better outcomes than CBD added to a fixed existing regimen without adjustment.
Related Articles
- → CBD Oil for Sleep and Multiple Sclerosis: Nocturnal Spasticity, MS Fatigue Paradox, and Six Co-Equal Sleep Disruption Mechanisms
- → CBD Oil for Sleep and Traumatic Brain Injury: Hypocretin Neuron Loss, Glymphatic Clearance, and Post-Concussion Sleep
- → CBD Oil for Sleep and Chronic Pain: Central Sensitization, the Descending Inhibitory System, and Nocturnal Pain Amplification
- → CBD Oil for Sleep and Restless Leg Syndrome: Dopaminergic Dysregulation, Iron-Ferritin Signaling, and Spinal Sensorimotor Gating
- → Nano CBD Oil: Why Nanoemulsion Bioavailability Changes Everything About CBD Dosing
References
- Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
- Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
- Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
- Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
- Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352
Medical Disclaimer
This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including spinal cord injury, autonomic dysreflexia, neuropathic pain, spasticity, or any sleep disorder. CBD oil is not a substitute for SCI rehabilitation care or physician-directed spinal cord injury management. Autonomic dysreflexia is a medical emergency — if you experience a sudden severe headache, hypertension, sweating, or flushing, follow your emergency AD management protocol and seek immediate medical attention; do not delay this response to use CBD. Patients on baclofen, tizanidine, gabapentin, opioids, or anticholinergic agents for SCI must discuss CBD use with their physiatrist or SCI managing physician. Patients with cervical SCI at high risk for sleep-disordered breathing should undergo formal sleep study evaluation before attributing sleep disruption solely to other SCI mechanisms. The statements in this article have not been evaluated by the Food and Drug Administration. Individual responses to CBD vary.
